Paper30833190
OVA66 promotes tumour angiogenesis and progression through enhancing autocrine VEGF-VEGFR2 signalling.
Song F and 6 others. EBioMedicine, 2019. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. OVA66 promotes tumour angiogenesis and progression through enhancing autocrine VEGF-VEGFR2 signalling. Papers, record 30833190. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30833190
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- OVA66 promotes tumour angiogenesis and progression through enhancing autocrine VEGF-VEGFR2 signalling.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Autocrine Communication | Major topic |
| Neovascularization, Pathologic | Major topic |
| Ovarian Neoplasms | Major topic |
| Vascular Endothelial Growth Factor A | Major topic |
| Vascular Endothelial Growth Factor Receptor-2 | Major topic |
| Animals | |
| Antigens, Neoplasm | |
| Female | |
| HeLa Cells | |
| Humans | |
| Mice | |
| Signal Transduction |
Source PubMed
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11416219 | CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. | Proc Natl Acad Sci U S A | 2001 | https://conductscience.org/library/papers/11416219 | PubMed |
| 2 | 18534745 | RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells. | Cancer Lett | 2008 | https://conductscience.org/library/papers/18534745 | PubMed |
| 3 | 18754882 | Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity. | Cancer Sci | 2008 | https://conductscience.org/library/papers/18754882 | PubMed |
| 4 | 19004006 | Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. | Int J Cancer | 2009 | https://conductscience.org/library/papers/19004006 | PubMed |
| 5 | 20141840 | Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. | Cell | 2010 | https://conductscience.org/library/papers/20141840 | PubMed |
| 6 | 20606083 | Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20606083 | PubMed |
| 7 | 22101807 | Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. | Cancer Metastasis Rev | 2012 | https://conductscience.org/library/papers/22101807 | PubMed |
| 8 | 22182449 | Blockade of VEGF-A suppresses tumor growth via inhibition of autocrine signaling through FAK and AKT. | Cancer Lett | 2012 | https://conductscience.org/library/papers/22182449 | PubMed |
| 9 | 22393126 | Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. | J Exp Med | 2012 | https://conductscience.org/library/papers/22393126 | PubMed |
| 10 | 22693250 | VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. | Cancer Res | 2012 | https://conductscience.org/library/papers/22693250 | PubMed |
| 11 | 23257828 | Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion. | Cell Adh Migr | 2012 | https://conductscience.org/library/papers/23257828 | PubMed |
| 12 | 23454747 | Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. | J Clin Invest | 2013 | https://conductscience.org/library/papers/23454747 | PubMed |
| 13 | 24120473 | Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway. | Gastroenterology | 2014 | https://conductscience.org/library/papers/24120473 | PubMed |
| 14 | 24263190 | VEGF targets the tumour cell. | Nat Rev Cancer | 2013 | https://conductscience.org/library/papers/24263190 | PubMed |
| 15 | 24633332 | OVA66, a tumor associated protein, induces oncogenic transformation of NIH3T3 cells. | PLoS One | 2014 | https://conductscience.org/library/papers/24633332 | PubMed |
| 16 | 24667688 | OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells. | Carcinogenesis | 2014 | https://conductscience.org/library/papers/24667688 | PubMed |
| 17 | 24849467 | Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. | Hepatology | 2014 | https://conductscience.org/library/papers/24849467 | PubMed |
| 18 | 25889301 | Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer. | Mol Cancer | 2015 | https://conductscience.org/library/papers/25889301 | PubMed |
| 19 | 26115797 | Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26115797 | PubMed |
| 20 | 27025186 | Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. | Lancet | 2016 | https://conductscience.org/library/papers/27025186 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42897126 | Cytokine context shapes antigen-presenting and matrix-producing states of cancer-associated fibroblasts. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42897126 | PubMed |
| 42190107 | Systemic cancer risk profile in neovascular age-related macular degeneration: insights into shared aging-related mechanisms from a nationwide population-based study. | Aging (Albany NY) | 2026 | https://conductscience.org/library/papers/42190107 | PubMed |
| 41331117 | β-Lapachone sensitizes glioblastoma to Temozolomide by inhibiting NF-κB signaling. | Funct Integr Genomics | 2025 | https://conductscience.org/library/papers/41331117 | PubMed |
| 39802400 | Valosin-containing protein (VCP), a component of tumor-derived extracellular vesicles, impairs the barrier integrity of brain microvascular endothelial cells. | BBA Adv | 2025 | https://conductscience.org/library/papers/39802400 | PubMed |
| 37338527 | Identifying the role of NUDCD1 in human tumors from clinical and molecular mechanisms: a study based on comprehensive bioinformatics and experimental validation. | Aging (Albany NY) | 2023 | https://conductscience.org/library/papers/37338527 | PubMed |
| 36835224 | Renin-Angiotensin-Aldosterone System Inhibitors and Development of Gynecologic Cancers: A 23 Million Individual Population-Based Study. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36835224 | PubMed |
| 36402931 | Mast cells inhibit colorectal cancer development by inducing ER stress through secreting Cystatin C. | Oncogene | 2023 | https://conductscience.org/library/papers/36402931 | PubMed |
| 36361682 | Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36361682 | PubMed |
| 36358584 | Ishophloroglucin A Ameliorates VEGF-Induced Epithelial-Mesenchymal Transition via VEGFR2 Pathway Inhibition in Microgravity-Stimulated Human Retinal Pigment Epithelial Cells. | Antioxidants (Basel) | 2022 | https://conductscience.org/library/papers/36358584 | PubMed |
| 35476233 | miR-144 inhibits the IGF1R-ERK1/2 signaling pathway via NUDCD1 to suppress the proliferation and metastasis of colorectal cancer cells: a study based on bioinformatics and in vitro and in vivo verification. | J Cancer Res Clin Oncol | 2022 | https://conductscience.org/library/papers/35476233 | PubMed |
| 34975330 | Exosomal LBH inhibits epithelial-mesenchymal transition and angiogenesis in nasopharyngeal carcinoma via downregulating VEGFA signaling. | Int J Biol Sci | 2022 | https://conductscience.org/library/papers/34975330 | PubMed |
| 34867402 | Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34867402 | PubMed |
| 34325402 | NUDCD1 knockdown inhibits the proliferation, migration, and invasion of pancreatic cancer via the EMT process. | Aging (Albany NY) | 2021 | https://conductscience.org/library/papers/34325402 | PubMed |
| 34217063 | Nox2 impairs VEGF-A-induced angiogenesis in placenta via mitochondrial ROS-STAT3 pathway. | Redox Biol | 2021 | https://conductscience.org/library/papers/34217063 | PubMed |
| 34135585 | Dual-Ligand-Modified Liposomes Co-Loaded with Anti-Angiogenic and Chemotherapeutic Drugs for Inhibiting Tumor Angiogenesis and Metastasis. | Int J Nanomedicine | 2021 | https://conductscience.org/library/papers/34135585 | PubMed |
| 34050127 | Nuclear exosome HMGB3 secreted by nasopharyngeal carcinoma cells promotes tumour metastasis by inducing angiogenesis. | Cell Death Dis | 2021 | https://conductscience.org/library/papers/34050127 | PubMed |
| 33673178 | Angiotensin II and Angiotensin Receptors 1 and 2-Multifunctional System in Cells Biology, What Do We Know? | Cells | 2021 | https://conductscience.org/library/papers/33673178 | PubMed |
| 33193893 | VEGF promotes migration and invasion by regulating EMT and MMPs in nasopharyngeal carcinoma. | J Cancer | 2020 | https://conductscience.org/library/papers/33193893 | PubMed |
| 31777993 | RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply. | Cancer Sci | 2020 | https://conductscience.org/library/papers/31777993 | PubMed |
Genes19
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30833190
GET https://conductscience.org/api/papers/v1/30833190/references?page=2